Medscape May 7, 2024
Deepa Varma

TOPLINE:

Overall, patients with solid tumors who receive an investigational cancer drug experience small progression-free survival (PFS) and overall survival benefits but much higher toxicity than those who receive a control intervention.

METHODOLOGY:

  • The view that patients with cancer benefit from access to investigational drugs in the clinical trial setting is widely held but does necessarily align with trial findings, which often show limited evidence of a clinical benefit. First, most investigational treatments assessed in clinical trials fail to gain regulatory approval, and the minority that are approved tend to offer minimal clinical benefit, experts explained.
  • To estimate the survival benefit and toxicities associated with receiving experimental treatments, researchers conducted a meta-analysis of 128 trials comprising 141 comparisons of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Patient / Consumer, Provider, Trends
Balancing Weight-loss Medication Cost and Care
Marijuana rescheduling moves businesses into ‘uncharted territory’
Reimagining Healthcare Delivery - 2
The Powerful Hospice Lessons of Jimmy Carter
‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care

Share This Article